nach oben

Erschienen in:

2024 | OriginalPaper | Buchkapitel

16. Neurotoxizität

verfasst von : Berit Jordan, Anita Margulies

Erschienen in: Onkologische Krankenpflege

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei der Behandlung maligner Erkrankungen können unerwünschte Wirkungen wie die Neurotoxizität kurz- und langfristig die Lebensqualität des Patienten wesentlich beeinträchtigen. Neurotoxizitäten können sowohl reversibel als auch irreversibel sein. Die Pflegenden können durch gute Beobachtung der Patienten und deren Beratung dazu beitragen, dass neurologische Symptome frühzeitig erkannt, medizinische Maßnahmen daher rechtzeitig eingeleitet und somit Neurotoxizitäten vermindert werden können. Kommt es dennoch zu irreversiblen neurologischen Schäden, können gezielte pflegerische Interventionen und die Zusammenarbeit mit anderen Disziplinen, z. B. der Physiotherapie und Ergotherapie, den Patienten die Aufrechterhaltung von möglichst vielen Aktivitäten des täglichen Lebens ermöglichen.

Vorheriges Kapitel Schmerz

Nächstes Kapitel Atemnot

Albany C et al (2021) Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer 29(11):7129–7130. https://doi.org/10.1007/s00520-021-06523-zCrossRefPubMed

Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U (2021) Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 9(2):385–450CrossRefPubMedPubMedCentral

Christie LA et al (2012) Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapie. Clin Cancer Res 18:1954–1965CrossRefPubMed

Jordan B, Margulies A et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319CrossRefPubMed

Jordan B, Benesova K, Hassel JC, Wick W, Jordan K (2021) How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open 6(6):100317CrossRefPubMedPubMedCentral

Jordan B, Jahn F, Beckmann J, Unverzagt S, Müller-Tidow C and Jordan K (2016) „Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review.“ Oncology 90(6):299–306

Kleckner IR, Kamen C, Gewandter JS et al (2018) Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26(4):1019–1028CrossRefPubMed

Loprinzi CL, Lacchetti C et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. JCO 38:3325–3345. Retr. 2022 May

Maihöfner C, Diel I, Tesch H et al (2021) Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer 29(8):4223–4238CrossRefPubMedPubMedCentral

Mocquot P, Mossazadeh Y, Lapierre L et al (2022) The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther 47(9):1337–1351CrossRefPubMedPubMedCentral

Morris EC, Neelapu SS et al (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85–96CrossRefPubMed

Paice J (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2, Suppl 1):S8–S19CrossRefPubMed

Rosenbaek F, Holm HS, Hjelmborg JVB et al (2020) Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer. Support Care Cancer 28(8):3763–3769CrossRefPubMed

Roth P, Winklhofer S, Müller AMS et al (2021) Neurological complications of cancer immunotherapy. Cancer Treat Rev 97:102189CrossRefPubMed

Salat K (2020) Chemotherapy-induced peripheral neuropathy – part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. Pharmacol Rep 72(3):508–527CrossRefPubMedPubMedCentral

Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813CrossRefPubMedPubMedCentral

Vardy J et al (2014) Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol 25:2404–2412CrossRefPubMedPubMedCentral

Baer B (2021) CAR T-cell therapy: updates in nursing management – chimeric antigen receptor t-cell therapy, cytokine release syndrome, neurotoxicity. CJON 25(3):255–258CrossRef

Bolz S et al (2021) Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci 22:100324CrossRefPubMedPubMedCentral

Cavaletti G (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454–462. https://doi.org/10.1093/annonc/mds329CrossRefPubMed

Cheng HL et al (2020) Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes 18:246CrossRefPubMedPubMedCentral

Frisina RD et al (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34(23):2712–2720CrossRefPubMedPubMedCentral

Grapp M, Argstatter H et al (2014) Music therapy for chronic tinnitus: variability of tinnitus pitch in the course of therapy. J Am Acad Audiol 25(4):335–342. https://doi.org/10.3766/jaaa.25.4.5CrossRefPubMed

Huehnchen P et al (2020) Cognitive impairment after cytotoxic chemotherapy. Neuro-Oncol Pract 7(1):11–21CrossRef

Kanzawa-Lee GA et al (2019) Mechanisms, predictors, and challenges in assessing and managing painful chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 35(3):253–260CrossRefPubMedPubMedCentral

Knoerl R et al (2020) Proactive rehabilitation for chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 36(1):150983CrossRefPubMed

Kurcio KR (2016) Chemotherapy-induced peripheral neuropathy, scales, questionnaires, instruments, psychometric properties. CJON 20(2):144–151CrossRef

Laforgia M et al (2021) Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. Int J Mol Sci 22(4):1980CrossRefPubMedPubMedCentral

Przybylyski A, Esper P (2016) Early recognition and management of posterior reversible encephalopathy syndrome: a newly recognized complication in patients receiving tyrosine kinase inhibitors biotherapy, targeted therapies, leukemia, lymphoma, hematology, management issues, neurotoxicity, oral therapies. CJON 20(3):305–308CrossRef

S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. Langversion 1.3 – _Februar 2020 AWMF-Registernummer: 032/054OL

Sałat K (2020) Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep 72:486–507CrossRefPubMedPubMedCentral

Smith EM et al (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35(1):96–102CrossRefPubMed

Staff NP et al (2019) Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S26–S39. https://doi.org/10.1111/jns.12335CrossRefPubMedPubMedCentral

Vasquez S (2014) Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice. Ir J Med Sci 183(1):53–55CrossRefPubMed

Function Assessment of Chronic Illness Therapy. www.facit.org (Fragebogen zur Erfassung von Neurotoxizität, Fragebogen zur Erfassung der kognitiven Funktion)

www.tzb.de – Broschüre „Chemobrain“. Merk -und Konzentrationsstörungen bei Tumorpatienten

Titel: Neurotoxizität
verfasst von: Berit Jordan
Anita Margulies
Verlag: Springer Berlin Heidelberg
Buch: Onkologische Krankenpflege
Print ISBN: 978-3-662-67416-1

Electronic ISBN: 978-3-662-67417-8

Copyright-Jahr: 2024
DOI: https://doi.org/10.1007/978-3-662-67417-8_16

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten